[Appropriate use of blood components]

Abstract

Blood products are biological products derived from human blood. Japan currently meets its domestic needs with red cell products, platelet products, and plasma derivatives produced from blood, but this system could face challenges in the future. Blood transfusion therapy is only a replacement therapy that relieves symptoms, and should not worsen the patient's outcome. Blood transfusion therapy should also be based on evidence, and the Japan Society of Blood Transfusion and Cell Therapy has created "Blood Transfusion Guidelines Based on Scientific Evidence" and calls for its proper use. Although the transfusion triggers in this guideline are effective for considering the indication for blood transfusion, the necessity of blood transfusion is comprehensively judged by taking into account factors such as the pathology, severity of symptoms, and comorbidities in each patient. Hematologists and pediatricians who frequently use blood products need to be fully aware of the risks they pose and promote safer and more appropriate use.

Keywords: Autologous blood transfusion; Blood transfusion guidelines; Patient blood management; Trigger point blood transfusion.